Shandong Sito Bio-technology Co Ltd

The company’s capital structure shows a debt-to-equity ratio of 0.46, indicating moderate leverage, while its current ratio of 1.28 suggests acceptable short-term liquidity. However, the negative net cash position after subtracting total debt raises concerns about liquidity risk. The price-to-book ratio of 1.63 implies the market values the company at a premium to its book value, but the negative return on equity (-4.15%) and return on assets (-2.47%) highlight poor profitability relative to its asset base. Profitability metrics fall significantly below industry norms. The company reported a net loss of CNY 73.15 million and an operating loss of CNY 76.75 million, with a gross profit margin of 11.55%. These figures contrast with the industry’s median gross margin of 25-30%, suggesting operational inefficiencies or pricing pressures. The negative EBITDA and EV/EBITDA ratio of -47.84 further underscore the company’s unprofitability. The company operates three segments: Steroid Raw Materials, Steroidal Finished Drugs, and Non-Steroidal Finished Drugs. Revenue concentration data is not disclosed, but the Steroid Raw Materials segment is likely the largest contributor, given its core technological focus. Geographic exposure is not explicitly detailed, but the company is based in Shandong, China, and likely serves domestic and regional pharmaceutical markets. Growth appears constrained. Revenue for the latest period was CNY 1.02 billion, but the company reported a net loss. Outlook data is not provided, but the negative free cash flow (-CNY 24.36 million) and capital expenditure (-CNY 79.65 million) suggest ongoing investment without immediate returns. The risk assessment flags liquidity as medium, with dilution risk rated low, though the negative net cash position indicates potential refinancing needs. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. However, the operating cash flow of CNY 158.53 million suggests some cash generation, though insufficient to cover capital expenditures. The company’s risk profile is elevated by its negative net income and operating income, with a liquidity risk score of medium. The debt-to-equity ratio of 0.46 is relatively low, but the negative net cash position after debt suggests potential refinancing challenges.